Loading data for ARWR — first visit, this takes a few seconds.

알림

Arrowhead Pharmaceuticals... (ARWR)

NasdaqGS: ARWR · 실시간 가격 · USD

87.11

-0.36 (-0.41%)

종가 기준: Aug 21, 2026, 8:00 PM

87.02

-0.10%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.41% (1D)

데이터 없음

매수호가	80.89
시가총액	12.3B
매출 (ttm)	669.49M
순이익 (ttm)	-319.96M
	1.29
	-2.28
	n/a
	-17.89
P/B (ttm)	26.41
P/S (ttm)	18.33
실적 발표일	Nov 24, 2026

매도호가	92.9
거래량	1,052,698
평균 거래량 (20일)	2,061,053
시가	88.15
전일 종가	87.47
일중 범위	85.94 - 88.46
52주 범위	20.45 - 95.49
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ARWR 소개

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clini...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Dec 16, 1993

직원 수 711

상장 거래소 NasdaqGS

티커 ARWR

웹사이트 https://arrowheadpharma.com

전체 기업 정보

재무 실적

2025년 Arrowhead Pharmaceuticals의 매출은 829.45M로, 전년 3.55M 대비 23,258.15% 증가했습니다. 순이익은 -1.63M로, -99.73% 감소했습니다.

재무제표

어닝 서프라이즈

Arrowhead Pharmaceuticals가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $75.25M 예상치 하회 $0, 및 171.02% 전년 대비 성장.
EPS -1.36 예상치 하회 -0.13, 및 -7.94% 전년 대비 감소.

다음 실적 발표

Arrowhead Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 24, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · BioPharma Dive

‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

2주 전 · GuruFocus.com

Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust clinical progress and commercial growth, despite a wider net loss in Q3 2026.

2주 전 · MarketBeat

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlig...

3주 전 · Simply Wall St.

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones

Arrowhead Pharmaceuticals recently reported that its siRNA drug plozasiran met all primary and key secondary endpoints in two global Phase 3 trials for severe hypertriglyceridemia, while also completi...

1개월 전 · Investor's Business Daily

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday, leading the stock to skyrocket.

2 페이지 중 1